|
| 36967330 | Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer. | Bull Cancer | 2024 |
| 37806863 | [Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours]. | Bull Cancer | 2024 |
| 37771077 | Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii. | Histopathology | 2024 |
| 36370117 | Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group. | Mol Oncol | 2023 |
| 37758451 | Gestational choriocarcinoma. | Int J Gynecol Cancer | 2023 |
| 37633969 | Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor. | Cell Death Differ | 2023 |
| 37597580 | Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2023 |
| 37561982 | <i>ESR1</i> Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases. | JCO Precis Oncol | 2023 |
| 37756555 | Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer. | Clin Cancer Res | 2023 |
| 37907262 | The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma. | Int J Gynecol Cancer | 2023 |
| 37591609 | Low-grade serous ovarian cancer: expert consensus report on the state of the science. | Int J Gynecol Cancer | 2023 |
| 37699075 | Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment. | Clin Cancer Res | 2023 |
| 37945748 | Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial. | Oncogene | 2023 |
| 37650734 | NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer. | Future Oncol | 2023 |
| 37581616 | Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. | Clin Cancer Res | 2023 |
| 37783481 | European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors. | Int J Gynecol Cancer | 2023 |
| 37542936 | Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. | Eur J Cancer | 2023 |
| 37573039 | Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023 : actualisation selon les données publiées et/ou présentées en 2022. | Bull Cancer | 2023 |
| 37679206 | Gynecological carcinosarcomas: Overview and future perspectives. | Bull Cancer | 2023 |
| 37640446 | Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option? | Int J Gynecol Cancer | 2023 |
| 37532934 | Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. | Nature | 2023 |
| 37922687 | Surgery and HIPEC in relapse for all patients with ovarian cancer? | ESMO Open | 2023 |
| 37394316 | Do surgeons overestimate diaphragmatic peritoneal disease in interval debulking surgery of ovarian cancer? | Eur J Surg Oncol | 2023 |
| 37353806 | Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network. | J Transl Med | 2023 |
| 37222199 | Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients. | Curr Opin Oncol | 2023 |
| 37058687 | Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. | J Clin Oncol | 2023 |
| 37156482 | Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy. | J Natl Compr Canc Netw | 2023 |
| 37086595 | Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice. | Eur J Cancer | 2023 |
| 36990895 | [Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group]. | Bull Cancer | 2023 |
| 36948526 | Splenectomy in epithelial ovarian cancer surgery. | Int J Gynecol Cancer | 2023 |
| 37046702 | Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors. | Cancers (Basel) | 2023 |
| 37045734 | [Treatments for rare ovarian tumors: What's new?] | Bull Cancer | 2023 |
| 36980708 | CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. | Cancers (Basel) | 2023 |
| 37245441 | PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. | Eur J Cancer | 2023 |
| 37211045 | Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. | Ann Oncol | 2023 |
| 37210929 | Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study. | Gynecol Oncol | 2023 |
| 37444554 | Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. | Cancers (Basel) | 2023 |
| 37444551 | Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort. | Cancers (Basel) | 2023 |
| 37377900 | Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas. | Cancer Res Commun | 2023 |
| 37105063 | PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients. | Gynecol Oncol | 2023 |
| 37307879 | The KAT6B::KANSL1 Fusion Defines a New Uterine Sarcoma With Hybrid Endometrial Stromal Tumor and Smooth Muscle Tumor Features. | Mod Pathol | 2023 |
| 37271639 | Selinexor in patients with advanced and recurrent endometrial cancer. | Curr Probl Cancer | 2023 |
| 37139242 | Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study. | Breast Cancer (Dove Med Press) | 2023 |
| 36971503 | Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection. | Oncologist | 2023 |
| 37202293 | [Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group]. | Bull Cancer | 2023 |
| 37097347 | CREB fusion-associated epithelioid mesenchymal neoplasms of the female adnexa: three cases documenting a novel location of an emerging entity and further highlighting an ambiguous misleading immunophenotype. | Virchows Arch | 2023 |
| 37364234 | Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma. | JCO Precis Oncol | 2023 |
| 37429302 | Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. | Lancet Oncol | 2023 |
| 37062646 | [Uterin sarcoma, high-grade stroma, indifferenciated, referential]. | Bull Cancer | 2023 |
| 36656928 | Heritable defects in telomere and mitotic function selectively predispose to sarcomas. | Science | 2023 |